Swiss National Bank bought a new stake in RadNet, Inc. (NASDAQ:RDNT) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 64,500 shares of the medical research company’s stock, valued at approximately $651,000. Swiss National Bank owned approximately 0.14% of RadNet at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Teacher Retirement System of Texas purchased a new position in RadNet in the 4th quarter valued at about $128,000. American Century Companies Inc. acquired a new position in shares of RadNet during the 4th quarter valued at about $216,000. Beck Mack & Oliver LLC increased its stake in shares of RadNet by 60.9% during the 4th quarter. Beck Mack & Oliver LLC now owns 352,916 shares of the medical research company’s stock valued at $3,564,000 after acquiring an additional 133,515 shares during the last quarter. Alambic Investment Management L.P. acquired a new position in shares of RadNet during the 4th quarter valued at about $176,000. Finally, Strs Ohio increased its stake in shares of RadNet by 12.5% during the 4th quarter. Strs Ohio now owns 70,900 shares of the medical research company’s stock valued at $716,000 after acquiring an additional 7,900 shares during the last quarter. Institutional investors own 55.82% of the company’s stock.
In other news, VP Mark Stolper sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $13.19, for a total transaction of $197,850.00. Following the completion of the transaction, the vice president now directly owns 130,319 shares in the company, valued at approximately $1,718,907.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey L. Linden sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $13.09, for a total value of $130,900.00. Following the transaction, the insider now owns 922,001 shares of the company’s stock, valued at $12,068,993.09. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 108,927 shares of company stock valued at $1,405,852. Company insiders own 9.36% of the company’s stock.
RDNT has been the subject of a number of research analyst reports. BidaskClub raised shares of RadNet from a “hold” rating to a “buy” rating in a research note on Wednesday, March 14th. Jefferies Group set a $14.00 target price on shares of RadNet and gave the stock a “buy” rating in a research report on Thursday, March 8th. Finally, Zacks Investment Research raised shares of RadNet from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Wednesday, March 21st. Two equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. RadNet has an average rating of “Strong Buy” and a consensus target price of $14.75.
NASDAQ:RDNT traded down $0.15 during trading hours on Friday, hitting $14.40. The stock had a trading volume of 333,855 shares, compared to its average volume of 501,945. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 8.22. RadNet, Inc. has a 1-year low of $5.65 and a 1-year high of $14.55. The company has a market capitalization of $701.78, a price-to-earnings ratio of 49.66, a price-to-earnings-growth ratio of 3.37 and a beta of 0.39.
RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Thursday, March 8th. The medical research company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.01). RadNet had a net margin of 0.01% and a return on equity of 26.01%. The firm had revenue of $235.50 million during the quarter, compared to analyst estimates of $228.46 million. During the same period last year, the business earned $0.08 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. equities analysts anticipate that RadNet, Inc. will post 0.54 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Swiss National Bank Invests $651,000 in RadNet, Inc. (NASDAQ:RDNT) Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/swiss-national-bank-invests-651000-in-radnet-inc-rdnt-stock.html.
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.